Portfolio Manager Factsheet
Following an extended period of volatility in the fourth quarter of 2018, January saw significant strength across both biotechnology stocks and the broader markets. The return of M&A activity, in particular the acquisition of Celgene by Bristol-Myers Squibb, reinvigorated investor interest in biotechnology.
The Biotech Growth Trust PLC conducts its affairs so that its shares can be recommended by independent financial advisers (IFAs) to retail private investors. The shares are excluded from the Financial Conduct Authority's (FCA's) restrictions which apply to non-mainstream investment products because they are shares in a UK-listed investment trust.